SCHEMBL2382446

SCHEMBL2382446

CCOC(=O)c1c(O)c2cc(I)ccc2n(C)c1=O

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.69
KDM4E B2RXH2 6/20 0.69
SMN1; SMN2 Q16637 4/20 0.57
LMNA P02545 4/20 0.50
NPC1 O15118 1/20 0.50
ALOX15 P16050 1/20 0.50
RECQL P46063 1/20 0.49
HTT P42858 1/20 0.48
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
POLB P06746 2/20 0.46
MEN1 O00255 1/20 0.46
PABPC1 P11940 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 2/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5525935 0.87 ALDH1A1 (0.72) ALDH1A1KDM4ESMN1; SMN2LMNANPC1
SCHEMBL15154629 0.86 ALDH1A1 (0.70) ALDH1A1KDM4ESMN1; SMN2LMNANPC1
SCHEMBL14607235 0.85 ALDH1A1 (0.66) ALDH1A1KDM4ESMN1; SMN2LMNANPC1
SCHEMBL5530559 0.85 ALDH1A1 (0.76) ALDH1A1KDM4ESMN1; SMN2LMNANPC1
SCHEMBL5529472 0.85 ALDH1A1 (0.69) ALDH1A1KDM4ESMN1; SMN2LMNANPC1
SCHEMBL15966805 0.85 ALDH1A1 (0.77) ALDH1A1KDM4ESMN1; SMN2LMNANPC1
SCHEMBL31329665 0.85 ALDH1A1 (0.69) ALDH1A1KDM4ESMN1; SMN2LMNANPC1
SCHEMBL11383580 0.84 ALDH1A1 (0.67) ALDH1A1KDM4ESMN1; SMN2LMNANPC1
SCHEMBL2382614 0.83 HIF1A (0.54) ALDH1A1KDM4ESMN1; SMN2NPC1ALOX15
SCHEMBL9273846 0.83 ALDH1A1 (0.66) ALDH1A1KDM4ESMN1; SMN2LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960363-B1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF AMGEN INC (US) 2014-01-22 EP disclosed
EP-1960363-B1 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF AMGEN INC (US) 2014-01-22 EP disclosed
EP-2142509-B1 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2011-09-15 US disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed
EP-1960363-A2 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF Amgen, Inc. (US) 2008-08-27 EP disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof AMGEN INC. 2007-10-25 US disclosed
WO-2007070359-A2 QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase EGLN3, HIF1AN, EGLN2 ALDH1A1 191/4885KDM4E 336/4885SMN1; SMN2 4791/4885
US-20070249605-A1 Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof EGLN3, HIF1AN, EGLN2 ALDH1A1 298/4885KDM4E 449/4885SMN1; SMN2 4545/4885
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE HIF1AN, EGLN3, EGLN2 ALDH1A1 145/4885KDM4E 126/4885SMN1; SMN2 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.